← Leaderboards
Harvey Michael Friedman
University Of Pennsylvania
$28,257,678
Attributed
$29,186,413
Total exposure
28
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,186,413 · 28
By mechanism
R01$15,069,652 · 5
U01$5,087,393 · 1
T32$3,309,753 · 2
M01$2,526,119 · 14
P30$2,260,438 · 3
R21$425,596 · 1
Top collaborators
- Audrey Ragan Odom John4 shared
- Sita Awasthi2 shared
- Chris Bailey-Kellogg1 shared
- Benjamin Delbert Brooks1 shared
- Gary H Cohen1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Francis C Luca$3,978,400
- Gary H Cohen$11,413,390
- Sita Awasthi$212,798
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationGrantHiv InfectionsGenital HerpesComplementVaccine DevelopmentInfectionVirusGlycoproteinsDrug Screening /EvaluationBaseImmunityClinical TrialsHerpesviridae VaccineClinical Trial Phase IAntibodiesImmuneProgramsVaccinesRecurrenceMediatingAids Therapy
Grant awards (129)
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes$812,498
R01 · FY2025 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$283,463
T32 · FY2025 · AI
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes$812,498
R01 · FY2024 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$250,545
T32 · FY2024 · AI
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes$812,498
R01 · FY2023 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$234,803
T32 · FY2023 · AI
A vaccine for genital herpes that achieves sterilizing immunity$788,448
R01 · FY2022 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$235,840
T32 · FY2022 · AI
A vaccine for genital herpes that achieves sterilizing immunity$783,564
R01 · FY2021 · AI · contact PI
A vaccine for genital herpes that achieves sterilizing immunity$796,177
R01 · FY2020 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$229,907
T32 · FY2020 · AI · contact PI
A vaccine for genital herpes that achieves sterilizing immunity$818,356
R01 · FY2019 · AI · contact PI
Improving HSV-2 vaccine efficacy by focusing antibody epitope coverage.$284,815
R41 · FY2019 · AI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$212,190
T32 · FY2019 · AI · contact PI
HSV-2 immune evasion as a virulence factor$400,000
R01 · FY2018 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$195,114
T32 · FY2018 · AI · contact PI
International Core$164,428
P30 · FY2018 · AI · contact PI
Mentoring/ Career Development Core$50,057
U54 · FY2018 · CA · contact PI
HSV-2 immune evasion as a virulence factor$400,000
R01 · FY2017 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$216,703
T32 · FY2017 · AI · contact PI
International Core$167,840
P30 · FY2017 · AI · contact PI
Mentoring/ Career Development Core$52,239
U54 · FY2017 · CA · contact PI
HSV-2 immune evasion as a virulence factor$499,999
R01 · FY2016 · AI · contact PI
Combined Adult and Pediatric Infectious Disease Postdoctoral Training Grant$213,256
T32 · FY2016 · AI · contact PI
International Core$167,466
P30 · FY2016 · AI · contact PI
Mentoring/ Career Development Core$3,585
U54 · FY2016 · CA · contact PI
HSV-2 immune evasion as a virulence factor$400,000
R01 · FY2015 · AI · contact PI
International Core$179,770
P30 · FY2015 · AI · contact PI
Mentoring/ Career Development Core$53,620
U54 · FY2015 · CA · contact PI
HSV-2 immune evasion as a virulence factor$400,000
R01 · FY2014 · AI · contact PI
Blocking immune evasion as a novel immunotherapy for recurrent HSV-2 infection$199,998
R21 · FY2014 · AI · contact PI
International Core$176,811
P30 · FY2014 · AI · contact PI
Mentoring/ Career Development Core$63,146
U54 · FY2014 · CA · contact PI
International$237,449
P30 · FY2013 · AI · contact PI
Blocking immune evasion as a novel immunotherapy for recurrent HSV-2 infection$225,598
R21 · FY2013 · AI · contact PI
International$175,670
P30 · FY2012 · AI · contact PI
International$287,196
P30 · FY2011 · AI · contact PI
Blocking immune evasion as a novel HSV vaccine approach$386,527
R01 · FY2010 · HL · contact PI
International$283,318
P30 · FY2010 · AI · contact PI
Postdoctoral Training Grant in Infectious Diseases$89,601
T32 · FY2010 · AI · contact PI
Blocking immune evasion as a novel HSV vaccine approach$386,737
R01 · FY2009 · HL · contact PI
Herpes Simplex Virus FC Receptor$368,914
R01 · FY2009 · AI · contact PI
International$255,069
P30 · FY2009 · AI · contact PI
Postdoctoral Training Grant in Infectious Diseases$81,378
T32 · FY2009 · AI · contact PI
Herpes Simplex Virus FC Receptor$22,653
R01 · FY2009 · AI · contact PI
Blocking immune evasion as a novel HSV vaccine approach$386,941
R01 · FY2008 · HL · contact PI
Herpes Simplex Virus FC Receptor$294,304
R01 · FY2008 · AI · contact PI
Postdoctoral Training Grant in Infectious Diseases$138,342
T32 · FY2008 · AI · contact PI
Blocking immune evasion as a nevel HSV vaccine approach$387,140
R01 · FY2007 · HL · contact PI
Herpes Simplex Virus FC Receptor$292,921
R01 · FY2007 · AI · contact PI
Postdoctoral Training Grant in Infectious Diseases$134,071
T32 · FY2007 · AI · contact PI
VIRUS & IMMUNE INJURY TO VESSEL WALL CELLS$386,938
R01 · FY2006 · HL · contact PI
Herpes Simplex Virus FC Receptor$307,711
R01 · FY2006 · AI · contact PI
Postdoctoral Training Grant in Infectious Diseases$143,065
T32 · FY2006 · AI · contact PI
VIRUS &IMMUNE INJURY TO VESSEL WALL CELLS$396,250
R01 · FY2005 · HL
HERPES SIMPLEX VIRUS IMMUNE EVASION IN HIV SUBJECTS$294,810
R01 · FY2005 · DE
POSTDOCTORAL TRAINING GRANT IN INFECTIOUS DISEASES$137,069
T32 · FY2005 · AI
ACTG A5001: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED TRIALS$134,577
M01 · FY2005 · RR
COMPARISON OF LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR$66,496
M01 · FY2005 · RR
PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV SUBJECTS$49,872
M01 · FY2005 · RR
BETA-D-2, DAPD, VERSUS DAPD PLUS MMF IN TREATMENT HIV SUBJECTS$32,457
M01 · FY2005 · RR
CRYOPRESERVATION EVALUATION IN HIV SUBJECTS$14,249
M01 · FY2005 · RR
ACTG A5116: SIMPLIFIED REGIMENS REGIMEN VS A NUCLEOSIDE-SPARING REGIMEN$7,125
M01 · FY2005 · RR
VIRUS &IMMUNE INJURY TO VESSEL WALL CELLS$396,250
R01 · FY2004 · HL
HERPES SIMPLEX VIRUS IMMUNE EVASION IN HIV SUBJECTS$294,810
R01 · FY2004 · DE
ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$112,658
M01 · FY2004 · RR
POSTDOCTORAL TRAINING GRANT IN INFECTIOUS DISEASES$100,673
T32 · FY2004 · AI
3 Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection$65,224
M01 · FY2004 · RR
HIV INFECTED SUBJECTS WHO HAVE 200 HIV-1 RNA COPIES/ML$11,011
M01 · FY2004 · RR
LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RIT$10,165
M01 · FY2004 · RR
BETA-D-2,6-DIAMINOPURINE DIOXOLANE VERSUS DAPD PLUS MYCOPHENOLATE MOFETIL$6,777
M01 · FY2004 · RR
VIRUS &IMMUNE INJURY TO VESSEL WALL CELLS$396,250
R01 · FY2003 · HL
HERPES SIMPLEX VIRUS IMMUNE EVASION IN HIV SUBJECTS$294,810
R01 · FY2003 · DE
POSTDOCTORAL TRAINING GRANT IN INFECTIOUS DISEASES$143,266
T32 · FY2003 · AI
AIDS CLINICAL TRIALS UNIT$1,718,471
U01 · FY2002 · AI
VIRUS &IMMUNE INJURY TO VESSEL WALL CELLS$396,250
R01 · FY2002 · HL
HERPES SIMPLEX VIRUS IMMUNE EVASION IN HIV SUBJECTS$294,810
R01 · FY2002 · DE
HERPES SIMPLEX VIRUS FC RECEPTOR$233,070
R01 · FY2002 · AI
POSTDOCTORAL TRAINING GRANT IN INFECTIOUS DISEASES$142,856
T32 · FY2002 · AI
HSV 007--SKBS HSV VACCINE TO PREVENT GENITAL HERPES IN HEALTHY SUBJECTS$124,146
M01 · FY2002 · RR
ACTG 360-- PROSPECTIVE STUDY OF HIV WRT CMV BURDEN ENDORGAN DISEASE$124,146
M01 · FY2002 · RR
HSV107--HERPES SIMPLEX VACCINE (GD2T) IN HSV + OR - CONSORTS WITH GENITAL HERPES$124,146
M01 · FY2002 · RR
SB-265805 COMPARED WITH CEFUROXIME AXETIL IN ACUTE SINUS$124,146
M01 · FY2002 · RR
ACTG 892: EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY$124,146
M01 · FY2002 · RR
ACTG 383:SUBJECTS W/ HEPATITIS C VIRUS &HUMAN IMMUNODEFICIENCY VIRUS$124,146
M01 · FY2002 · RR
CORE--CLINICAL FACILITY$0
P30 · FY2002 · AI
AIDS CLINICAL TRIALS UNIT$1,696,728
U01 · FY2001 · AI
HERPES SIMPLEX VIRUS IMMUNE EVASION IN HIV SUBJECTS$294,810
R01 · FY2001 · DE
HERPES SIMPLEX VIRUS FC RECEPTOR$226,280
R01 · FY2001 · AI
POSTDOCTORAL TRAINING GRANT IN INFECTIOUS DISEASES$127,611
T32 · FY2001 · AI
HSV 007--SKBS HSV VACCINE TO PREVENT GENITAL HERPES IN HEALTHY SUBJECTS$124,146
M01 · FY2001 · RR
SB-265805 COMPARED WITH CEFUROXIME AXETIL IN ACUTE SINUS$124,146
M01 · FY2001 · RR
ACTG 892: EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY$124,146
M01 · FY2001 · RR
ACTG 383:SUBJECTS W/ HEPATITIS C VIRUS &HUMAN IMMUNODEFICIENCY VIRUS$124,146
M01 · FY2001 · RR
ACTG 360-- PROSPECTIVE STUDY OF HIV WRT CMV BURDEN ENDORGAN DISEASE$124,146
M01 · FY2001 · RR
HSV107--HERPES SIMPLEX VACCINE (GD2T) IN HSV + OR - CONSORTS WITH GENITAL HERPES$124,146
M01 · FY2001 · RR
CORE--CLINICAL FACILITY$0
P30 · FY2001 · AI
ACTG 383:SUBJECTS W/ HEPATITIS C VIRUS &HUMAN IMMUNODEFICIENCY VIRUS$0
M01 · FY2001 · RR
ACTG 360-- PROSPECTIVE STUDY OF HIV WRT CMV BURDEN ENDORGAN DISEASE$0
M01 · FY2001 · RR
HSV107--HERPES SIMPLEX VACCINE (GD2T) IN HSV + OR - CONSORTS WITH GENITAL HERPES$0
M01 · FY2001 · RR
SB-265805 COMPARED WITH CEFUROXIME AXETIL IN ACUTE SINUS$0
M01 · FY2001 · RR
HSV 007--SKBS HSV VACCINE TO PREVENT GENITAL HERPES IN HEALTHY SUBJECTS$0
M01 · FY2001 · RR
CORE--CLINICAL FACILITY$0
P30 · FY2001 · AI
ACTG 892: EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY$0
M01 · FY2001 · RR
AIDS CLINICAL TRIALS UNIT$1,672,194
U01 · FY2000 · AI
VIRUS AND IMMUNE INJURY TO VESSEL WALL CELLS$386,737
R01 · FY2000 · HL
HERPES SIMPLEX VIRUS FC RECEPTOR$219,691
R01 · FY2000 · AI
HSV 16--HERPES SIMPLEX CANDIDATE VACCINE WITH MPL IN HSV PTS W/O GENITAL HERPES$187,536
M01 · FY2000 · RR
HSV 16--HERPES SIMPLEX CANDIDATE VACCINE WITH MPL IN HSV PTS W/O GENITAL HERPES$187,536
M01 · FY2000 · RR
CORE--CLINICAL FACILITY$165,421
P30 · FY2000 · AI
ACTG 892: EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY$25,114
M01 · FY2000 · RR
HSV107--HERPES SIMPLEX VACCINE (GD2T) IN HSV + OR - CONSORTS WITH GENITAL HERPES$25,114
M01 · FY2000 · RR
HSV 007--SKBS HSV VACCINE TO PREVENT GENITAL HERPES IN HEALTHY SUBJECTS$25,114
M01 · FY2000 · RR
ACTG 383:SUBJECTS W/ HEPATITIS C VIRUS &HUMAN IMMUNODEFICIENCY VIRUS$25,114
M01 · FY2000 · RR
ACTG 360-- PROSPECTIVE STUDY OF HIV WRT CMV BURDEN ENDORGAN DISEASE$25,114
M01 · FY2000 · RR
HSV 16--HERPES SIMPLEX CANDIDATE VACCINE WITH MPL IN HSV PTS W/O GENITAL HERPES$25,114
M01 · FY2000 · RR
ACTG 383:SUBJECTS W/ HEPATITIS C VIRUS &HUMAN IMMUNODEFICIENCY VIRUS$0
M01 · FY2000 · RR
HSV 007--SKBS HSV VACCINE TO PREVENT GENITAL HERPES IN HEALTHY SUBJECTS$0
M01 · FY2000 · RR
HSV107--HERPES SIMPLEX VACCINE (GD2T) IN HSV + OR - CONSORTS WITH GENITAL HERPES$0
M01 · FY2000 · RR
ACTG 360-- PROSPECTIVE STUDY OF HIV WRT CMV BURDEN ENDORGAN DISEASE$0
M01 · FY2000 · RR
ACTG 360-- PROSPECTIVE STUDY OF HIV WRT CMV BURDEN ENDORGAN DISEASE$0
M01 · FY2000 · RR
HSV107--HERPES SIMPLEX VACCINE (GD2T) IN HSV + OR - CONSORTS WITH GENITAL HERPES$0
M01 · FY2000 · RR
SB-265805 COMPARED WITH CEFUROXIME AXETIL IN ACUTE SINUS$0
M01 · FY2000 · RR
SB-265805 COMPARED WITH CEFUROXIME AXETIL IN ACUTE SINUS$0
M01 · FY2000 · RR
SB-265805 COMPARED WITH CEFUROXIME AXETIL IN ACUTE SINUS$0
M01 · FY2000 · RR
HSV 007--SKBS HSV VACCINE TO PREVENT GENITAL HERPES IN HEALTHY SUBJECTS$0
M01 · FY2000 · RR
ACTG 892: EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY$0
M01 · FY2000 · RR
ACTG 892: EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY$0
M01 · FY2000 · RR
ACTG 383:SUBJECTS W/ HEPATITIS C VIRUS &HUMAN IMMUNODEFICIENCY VIRUS$0
M01 · FY2000 · RR